Intravenous immunoglobulin therapy for autoimmune diseases

Therapeutic approaches for autoimmune diseases are primarily based on suppressive measures that down regulate an over productive immune system. The increasing availability of modern biological therapies has advanced the ability to target and to neutralize essential components of the immune response without experiencing the hazardous adverse effects caused by the traditional immunosuppressants. One of the noticeable examples of this approach is the increasing use of high-dose intravenous immunoglobulin (IVIg). IVIg mechanisms include modulating function of Fc receptors, interference with complement activation and cytokine network, provision of anti-idiotypic antibodies, regulation of cell growth, and effects on of T and B cells. In this review we gather existing information regarding IVIg mechanisms of action, clinical applications and its effects on various conditions.

[1]  D. S. Gordon,et al.  Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. , 2010, Arthritis and rheumatism.

[2]  J. Hooper.  Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations , 2008, Immunology and Allergy Clinics of North America.

[3]  R. Gold,et al.  Use of intravenous immunoglobulin and plasma exchange in neurological disease , 2008, Current opinion in neurology.

[4]  Y. Shoenfeld,et al.  What is the contents of the magic draft IVIg? , 2008, Autoimmunity reviews.

[5]  L. Zinman,et al.  IVIG Treatment for Myasthenia Gravis , 2008, Annals of the New York Academy of Sciences.

[6]  Y. Shoenfeld,et al.  Intravenous Immunoglobulin and Cytokines , 2007, Annals of the New York Academy of Sciences.

[7]  S. Jolles,et al.  Intravenous Immunoglobulin and Autoimmune Disease , 2007, Annals of the New York Academy of Sciences.

[8]  A. Tincani,et al.  Intravenous immunoglobulin in pregnancy: a chance for patients with an autoimmune disease. , 2007, The Israel Medical Association journal : IMAJ.

[9]  Y. Shoenfeld,et al.  BAFF, a New Target for Intravenous Immunoglobulin in Autoimmunity and Cancer , 2007, Journal of Clinical Immunology.

[10]  J. Ravetch,et al.  Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation , 2006, Science.

[11]  Y. Shoenfeld,et al.  Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. , 2006, Autoimmunity reviews.

[12]  A. Achiron,et al.  Long term safety of IVIg therapy in multiple sclerosis: 10 years experience , 2006, Autoimmunity.

[13]  Y. Shoenfeld,et al.  Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris , 2005, Clinical and experimental immunology.

[14]  Hans Lassmann,et al.  Multiple Sclerosis Pathology: Evolution of Pathogenetic Concepts , 2005, Brain pathology.

[15]  Y. Shoenfeld,et al.  Response of Vasculitic Peripheral Neuropathy to Intravenous Immunoglobulin , 2005, Annals of the New York Academy of Sciences.

[16]  R. Lemieux,et al.  Therapeutic intravenous immunoglobulins. , 2005, Molecular immunology.

[17]  S. Rizvi,et al.  Current approved options for treating patients with multiple sclerosis , 2004, Neurology.

[18]  K. Davison,et al.  Intravenous immunoglobulin (IVIg) for therapy‐resistant cutaneous lupus erythematosus (LE) , 2004, The Journal of dermatological treatment.

[19]  Y. Shoenfeld,et al.  Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis , 2003, Annals of the rheumatic diseases.

[20]  K. Bhol,et al.  Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. , 2003, European journal of dermatology : EJD.

[21]  Eric M. Billings,et al.  F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins , 2003, Nature Medicine.

[22]  J. Pollard,et al.  Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. , 2003, Immunity.

[23]  E. Ruocco,et al.  Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. , 2002, Archives of dermatology.

[24]  T. Maisonobe,et al.  Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. , 2002, Arthritis and rheumatism.

[25]  Y. Shoenfeld,et al.  Antiphospholipid antibody levels in intravenous immunoglobulin (IVIg) preparations , 2001, Lupus.

[26]  G. Comi,et al.  Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy , 2001, Annals of neurology.

[27]  L. Rauova,et al.  Adverse Effects of Intravenous Immunoglobulin Therapy in 56 Patients with Autoimmune Diseases , 2001, Pharmacology.

[28]  A. Górski,et al.  Intravenous Immunoglobulin Therapy Influences T cell Adhesion to Extracellular Matrix in Women with a History of Recurrent Spontaneous Abortions , 2000, American journal of reproductive immunology.

[29]  S. Kaveri,et al.  Idiotypic regulation of anti-factor VIII antibodies. , 2000, Haematologica.

[30]  Y. Shoenfeld,et al.  Intravenous immunoglobulin therapy of antiphospholipid syndrome. , 2000, Rheumatology.

[31]  M. Yaron,et al.  Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases , 2000, Annals of the rheumatic diseases.

[32]  J. Ioannidis,et al.  Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis , 1999, The Lancet.

[33]  Y. Shoenfeld,et al.  Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin , 1999, Lupus.

[34]  R. Lisak.  Intravenous Immunoglobulins in Multiple Sclerosis , 1998, Neurology.

[35]  Fontana,et al.  High‐Dose Intravenous Immunoglobulin Treatment Activates Complement In Vivo , 1998, Scandinavian journal of immunology.

[36]  M. Feinman,et al.  A Rational Basis for the Use of Combined Heparin/Aspirin and IVIG Immunotherapy in the Treatment of Recurrent IVF Failure Associated with Antiphospholipid Antibodies , 1998, American journal of reproductive immunology.

[37]  K. Bendtzen,et al.  Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. , 1998, Blood.

[38]  P. Puddu,et al.  Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus , 1997, Lupus.

[39]  M. Dalakas.  Intravenous Immune Globulin Therapy for Neurologic Diseases , 1997, Annals of Internal Medicine.

[40]  Y. Shoenfeld,et al.  Successful treatment of early secondary myelofibrosis in SLE with IVIG , 1997, Lupus.

[41]  G. Nahler,et al.  Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis , 1997, The Lancet.

[42]  Plasma-ExchangeSandoglobulinGuillain-Barré Syndrome Trial Group.  Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome , 1997, The Lancet.

[43]  W. Hacke,et al.  Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome , 1997 .

[44]  M. Kazatchkine,et al.  Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype. , 1996, Clinical and experimental rheumatology.

[45]  N. Yuki,et al.  Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies , 1996, Journal of the Neurological Sciences.

[46]  M. Galeazzi,et al.  Intravenous immunoglobulin therapy: modification of the immunofluorescence pattern in the skin of six patients with systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[47]  Mehta Ys,et al.  In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins. , 1996 .

[48]  V. Bril,et al.  Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome , 1996, Neurology.

[49]  Y. Shoenfeld,et al.  Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. , 1995, The Journal of rheumatology.

[50]  B. Becker,et al.  Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. , 1995, Journal of the American Society of Nephrology : JASN.

[51]  A. Amoroso,et al.  Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. , 1994, Journal of autoimmunity.

[52]  F. Dammacco,et al.  Pathogenic anti‐DNA idiotype‐reactive IgG in intravenous immunoglobulin preparations , 1994, Clinical and experimental immunology.

[53]  B. Wechsler,et al.  Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. , 1994, The Journal of rheumatology.

[54]  J. Dambrosia,et al.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. , 1993, The New England journal of medicine.

[55]  I. Lundkvist,et al.  Immune Modulatory Effects of Immunoglobulins on Cell‐Mediated Immune Responses In Vitro , 1993, Scandinavian journal of immunology.

[56]  Y. Shoenfeld,et al.  The Effect of Intravenous γ-Globulin on the Induction of Experimental Antiphospholipid Syndrome , 1993 .

[57]  I. Lundkvist,et al.  Spontaneous recovery from the Guillain-Barré syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. , 1993, Clinical immunology and immunopathology.

[58]  F. Mastaglia,et al.  Intravenous immunoglobulin for multifocal motor neuropathy , 1992, The Lancet.

[59]  A. Weetman,et al.  Analysis of anti-idiotypic antibodies against anti-microsomal antibodies in patients with thyroid autoimmunity. , 1992, Journal of autoimmunity.

[60]  P. Schmitz,et al.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. , 1992, The New England journal of medicine.

[61]  T. Barbui,et al.  In vivo efficacy of intravenous gammaglobulins in patients with lupus anticoagulant is not mediated by an anti‐idiotypic mechanism , 1991, American journal of hematology.

[62]  M. Kazatchkine,et al.  Anti‐idiotypes against anti‐neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis , 1991, Clinical and experimental immunology.

[63]  T. Ternynck,et al.  IgG autoantibody activity in normal mouse serum is controlled by IgM. , 1990, Journal of immunology.

[64]  M. Kazatchkine,et al.  Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. , 1989, Journal of immunology.

[65]  G. Pérez,et al.  LUPUS ANTICOAGULANT AND RECURRENT FETAL LOSS: SUCCESSFUL TREATMENT WITH GAMMAGLOBULIN , 1988, The Lancet.

[66]  M. Kazatchkine,et al.  ANTI-IDIOTYPIC SUPPRESSION OF AUTOANTIBODIES TO FACTOR VIII (ANTIHAEMOPHILIC FACTOR) BY HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN , 1984, The Lancet.

[67]  R. Kimberly,et al.  Modulation of mononuclear phagocyte function by intravenous gamma-globulin. , 1984, Journal of immunology.

[68]  C. Cunningham-Rundles,et al.  Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura , 1983 .

[69]  A. Salama,et al.  EFFECT OF INTRAVENOUS IMMUNOGLOBULIN IN IMMUNE THROMBOCYTOPENIA Competitive Inhibition of Reticuloendothelial System Function by Sequestration of Autologous Red Blood Cells? , 1983, The Lancet.

[70]  J. Fehr,et al.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. , 1982, The New England journal of medicine.

[71]  Dewhurst Cj.  VAGINAL SPECULUM FOR CHILDREN. , 1964 .

[72]  M. Marshall.  STERILISATION BY STEAM UNDER INCREASED PRESSURE; A THIRD COMMUNICATION TO THE MEDICAL RESEARCH COUNCIL BY THE WORKING PARTY ON PRESSURE-STEAM STERILISERS. , 1964, Lancet.

[73]  R. D. de Haan,et al.  Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. , 2009, The Cochrane database of systematic reviews.

[74]  Y. Shoenfeld,et al.  Anti-DNA and Antiphospholipid Antibodies in IVIG Preparations: In Vivo Study in Naive Mice , 2004, Journal of Clinical Immunology.

[75]  Y. Shoenfeld,et al.  Successful Treatment of Systemic Lupus Erythematosus Cerebritis with Intravenous Immunoglobulin , 1999, Clinical Rheumatology.

[76]  G. Nahler,et al.  Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. , 1997, Lancet.

[77]  S. Badakere,et al.  In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins. , 1996, Journal of postgraduate medicine.

[78]  Y. Shoenfeld,et al.  The effect of intravenous gamma-globulin on the induction of experimental antiphospholipid syndrome. , 1993, Clinical immunology and immunopathology.

[79]  L. Carreras,et al.  Neutralization of lupus anticoagulant activity by human immunoglobulin "in vitro". , 1992, Nouvelle revue francaise d'hematologie.

[80]  Carreras Lo,et al.  Neutralization of lupus anticoagulant activity by human immunoglobulin in vitro , 1992 .

[81]  K. Akashi,et al.  Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. , 1990, The Journal of rheumatology.

[82]  C. Cunningham-Rundles,et al.  Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. , 1983, Blood.